Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;24(12):1821-1828.
doi: 10.1007/s11912-022-01328-7. Epub 2022 Oct 4.

Immunotherapy in Biliary Tract Cancers: Where Are We?

Aparna Kalyan  1 , Harshit Khosla  2 , Richard D Kim  3
Affiliations
Review

Immunotherapy in Biliary Tract Cancers: Where Are We?

Aparna Kalyan et al. Curr Oncol Rep. 2022 Dec.

Abstract

Purpose of review: Biliary tract cancers (BTCs) are a heterogenous group of cancers arising from the biliary tract. The hallmark of these cancers is the advanced stage of presentation and a paucity of durable treatment options. Despite the advances in targeted therapy and immunotherapy in solid tumors, systemic cytotoxic chemotherapy has remained the mainstay for cholangiocarcinomas.

Recent findings: With advances in the understanding of the tumor microenvironment, genetic features, and inflammatory milieu, have led to the identification of tumor-infiltrating immune cells as indicators of prognosis and response to treatment in BTC. Through an improved comprehension of immunology, immuno-oncology is becoming another pillar of treatment along with traditional radiation, surgery, cytotoxic chemotherapy, and targeted therapies. This article reviews the evidence for immunotherapy use in cholangiocarcinoma, which still being in infancy, and offers promising new novel options for the management of biliary tract cancers.

Keywords: Biliary cancer; Cholangiocarcinoma; Immune Checkpoint Inhibitors; Immunotherapy; Targeted therapy.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. - DOI - PubMed - PMC
    1. Al-Rajabi R, Sun W. Immunotherapy in cholangiocarcinoma. Curr Opin Gastroenterol. 2021;37(2):105–11. - DOI - PubMed
    1. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. - DOI - PubMed
    1. Suleiman Y, Coppola D, Zibadi S, Dalia S, Juan T, Lee JK, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma. J Clin Oncol. 2015;33(3_suppl):294–294. https://doi.org/10.1200/jco.2015.33.3_suppl.294 .
    1. Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S. Interaction of B7–H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009;100(6):500–4. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources